z-logo
Premium
Elevation of neuron‐specific enolase in serum and cerebrospinal fluid of early stage Creutzfeldt–Jakob disease
Author(s) -
Kohira I.,
Tsuji T.,
Ishizu H.,
Takao Y.,
Wake A.,
Abe K.,
Kuroda S.
Publication year - 2000
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1034/j.1600-0404.2000.102006385.x
Subject(s) - enolase , cerebrospinal fluid , medicine , stage (stratigraphy) , gastroenterology , pathology , biology , immunohistochemistry , paleontology
Objective – To investigate the levels of neuron‐specific enolase (NSE) in serum and cerebrospinal fluid (CSF) of patients with early stage Creutzfeldt–Jakob disease (CJD). Methods – The levels of NSE in serum and CSF were examined in 6 cases with CJD patients. The levels of NSE in CSF were measured in 8 age matched control patients with other neurological diseases and the levels of serum NSE were also measured in another 8 age matched control patients with other neurological diseases. The groups of 8 age matched control patients consisted of 1 same patient and 7 different patients in the 2 control groups both for serum and CSF. Results – The level of serum NSE in CJD (17.3±7.0 ng/ml, mean±SD) was significantly higher than that of controls (6.5±1.6) ( P <0.02) as was the case in CSF (79.3±53.3 ng/ml) vs (9.6±2.9) ( P <0.03). Conclusion – Although mean NSE levels of CJD were higher in CSF than in the serum, there still is a case with higher serum NSE level than CSF. These results suggest that the mechanism of elevation of serum NSE may not be a simple leakage from CSF, and that the measurement of serum NSE level may be useful for diagnosis of early stage CJD.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here